MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-BR-26-0013244
Ajuras Pharmaceuticals Private Limited
Ajuras Pharmaceuticals Private Limited - trading in Nashik, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹2.99 Cr
▲ 15% YoY
Net profit · FY 2025
₹10.9 Lakh
Net margin 3.6%
EBITDA · FY 2025
₹16.34 Lakh
EBITDA margin 5.5%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹3 Lakh
Issued & subscribed
Company age
8 yrs
Est. 2018
Employees · EPFO
15
Provident fund records
Directors on board
3
As per MCA filings
About Ajuras Pharmaceuticals Private Limited
Data last updated:
Ajuras Pharmaceuticals Private Limited is a private limited company based in Nashik, Maharashtra, India. It operates in the specialised services segment of the trading and commerce sector. It was incorporated on 28 December 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2018PTC318865. Its GSTIN is 10AARCA7322B1Z7 (Bihar).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹3 Lakh. It is led by directors including Rupam Kumari (Managing Director) and Jitendra Kumar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at C/O – Pinki Purushottam Singh Flat No.B – 2 .Hari Sparsh Appt Barnes School Road, Nashik, Maharashtra, India – 422401.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.99 Cr, a growth of 15% compared to the previous year. For the same year it recorded a net profit of ₹10.9 Lakh (net margin 3.6%) and EBITDA of ₹16.34 Lakh (EBITDA margin 5.5%). Revenue has grown at a compounded annual rate (CAGR) of 22% over three years and 23% over five years.
The company has about 15 employees on its provident fund (EPFO) records.
Ajuras Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-BR-26-0013244).
Company details
CIN U51909MH2018PTC318865
Registration Number 318865
Incorporation Date 28 December 2018
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
MSME Classification Micro
Udyam Registration UDYAM-BR-26-0013244
Recognitions & Rankings of Ajuras Pharmaceuticals
Contact details
Ajuras Pharmaceuticals Private Limited's registered office is in Nashik, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered AddressC/O – Pinki Purushottam Singh Flat No.B – 2 .Hari Sparsh Appt Barnes School Road, Nashik, Maharashtra, India – 422401
- IndustryTrading, Specialty, Wholesale
To see the full contact details of Ajuras Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Ajuras Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Ajuras Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of Ajuras Pharmaceuticals Private Limited, buy the company report.
Financials of Ajuras Pharmaceuticals Private Limited
FY 2025 filings availableAjuras Pharmaceuticals Private Limited reported revenue of ₹2.99 Cr (up 15% YoY) for FY 2025.
Revenue · FY 2025
₹2.99 Cr ▲ 15%
Net profit · FY 2025
₹10.9 Lakh margin 3.6%
EBITDA · FY 2025
₹16.34 Lakh margin 5.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 15%
3 years · compounded
▲ 22%
5 years · compounded
▲ 23%
EBITDA CAGR growth
1 year
▲ 15%
3 years · compounded
▲ 43%
5 years · compounded
▲ 26%
Revenue has grown at a compounded annual rate (CAGR) of 23% over five years, including 15% growth in the latest year. EBITDA rose 15% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹16.34 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹10.9 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.5% | ||||
| Net Profit Margin | 3.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Ajuras Pharmaceuticals Private Limited, buy the company report.
Board of directors of Ajuras Pharmaceuticals Private Limited
Ajuras Pharmaceuticals has 3 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jitendra Kumar | Director | 28 Dec 2018 | 7 Years 9 Months | Current |
| Manish Kumar | Director | 28 Dec 2018 | 7 Years 9 Months | Current |
| Rupam Kumari | Managing Director | 01 Apr 2019 | 7 Years 6 Months | Current |
Legal cases
No court or tribunal cases involving Ajuras Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ajuras Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Ajuras Pharmaceuticals Private Limited has a workforce of 15 employees on its EPFO records as of Apr 10, 2024, across 1 active EPFO establishment.
Employee count
15
Active EPFO establishments
1
Employee growth
25%
GST
Ajuras Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AARCA7322B1Z7 | Bihar | Active | 16 May 2019 |
To see the full GST registrations and return filing status of Ajuras Pharmaceuticals Private Limited, buy the company report.
Recent activity
Ajuras Pharmaceuticals Private Limited has 3 board changes on record since 2018: 3 appointments. The latest: Rupam Kumari was appointed as Managing Director on 01 Apr 2019.
AGM
Ajuras Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Ajuras Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Appointed
Rupam Kumari was appointed as Managing Director.
Appointed
Jitendra Kumar was appointed as Director.
Appointed
Manish Kumar was appointed as Director.
Incorporation
28 Dec 2018
Ajuras Pharmaceuticals Private Limited was registered on 28 Dec 2018 with Roc Mumbai & aged 7 years 9 months as per MCA records.
Frequently asked questions
Ajuras Pharmaceuticals is an active private limited company based in Nashik, Maharashtra, India. The company works in specialty, within the trading industry. It was incorporated on 28 December 2018 (8+ years old) and is registered under CIN U51909MH2018PTC318865.
Ajuras Pharmaceuticals has 3 current directors:
- Rupam Kumari - Managing Director
- Jitendra Kumar - Director
- Manish Kumar - Director
The latest financial statements of Ajuras Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Ajuras Pharmaceuticals is 10AARCA7322B1Z7, registered in Bihar.
The CIN (Corporate Identification Number) of Ajuras Pharmaceuticals is U51909MH2018PTC318865. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ajuras Pharmaceuticals was incorporated on 28 December 2018, making it 8+ years old. It is registered with the Registrar of Companies, Mumbai.
Rupam Kumari was appointed as Managing Director on 01 Apr 2019. Jitendra Kumar was appointed as Director on 28 Dec 2018. Manish Kumar was appointed as Director on 28 Dec 2018.
Yes, Ajuras Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-BR-26-0013244).
The registered office of Ajuras Pharmaceuticals is at CO – Pinki Purushottam Singh Flat No.B – 2 .Hari Sparsh Appt Barnes School Road, Nashik, Maharashtra, India – 422401.
Ajuras Pharmaceuticals operates in the trading industry, in the specialty segment.